Antibe recently concluded a substantive endoscopic Phase 2B clinical trial in 244 healthy volunteers, in which it demonstrated an unequivocal GI safety advantage of ATB-346 as compared to naproxen, the most prescribed NSAID in the United States. This internal paper provides a more in-depth analysis of the data from this clinical trial, including summaries and discussion of the secondary endpoints. A peer-reviewed paper was subsequently published in February 2019 in the British Journal of Pharmacology.


This is an external link. Click “OK” to continue.